PURPOSE: To determine the mechanism through which topical mitomycin C prevents and treats corneal haze after photorefractive keratectomy (PRK) and to examine the effects of dosage and duration of exposure. METHODS: In 224 New Zealand rabbits, -9.0 diopter PRK with mitomycin C or balanced salt solution was performed. Haze level was graded at the slit-lamp. Rabbits were sacrificed at 4 hours, 24 hours, 4 weeks, or 6 months after surgery and immunohistochemistry was performed with TUNEL assay, Ki67, and alpha-SMA. RESULTS: TUNEL-positive apoptotic cells marginally increased in all mitomycin C groups whereas Ki67-positive mitotic cells decreased significantly following mitomycin C application. A greater decrease in myofibroblasts was noted with prophylactic mitomycin C treatment than therapeutic mitomycin C treatment. There was, however, an anterior stromal acellular zone (approximately 20% of the total stroma) in eyes treated with mitomycin C, which persisted to the maximum follow-up of 6 months. CONCLUSIONS: Mitomycin C treatment induces apoptosis of keratocytes and myofibroblasts, but the predominate effect in inhibiting or treating haze appears to be at the level of blocked replication of keratocytes or other progenitor cells of myofibroblasts. Treatment with 0.002% mitomycin C for 12 seconds to 1 minute appears to be just as effective as higher concentrations for longer duration in the rabbit model. However, a persistent decrease in keratocyte density in the anterior stroma could be a warning sign for future complications and treatment should be reserved for patients with significant risk of developing haze after PRK.
PURPOSE: To determine the mechanism through which topical mitomycin C prevents and treats corneal haze after photorefractive keratectomy (PRK) and to examine the effects of dosage and duration of exposure. METHODS: In 224 New Zealand rabbits, -9.0 diopter PRK with mitomycin C or balanced salt solution was performed. Haze level was graded at the slit-lamp. Rabbits were sacrificed at 4 hours, 24 hours, 4 weeks, or 6 months after surgery and immunohistochemistry was performed with TUNEL assay, Ki67, and alpha-SMA. RESULTS: TUNEL-positive apoptotic cells marginally increased in all mitomycin C groups whereas Ki67-positive mitotic cells decreased significantly following mitomycin C application. A greater decrease in myofibroblasts was noted with prophylactic mitomycin C treatment than therapeutic mitomycin C treatment. There was, however, an anterior stromal acellular zone (approximately 20% of the total stroma) in eyes treated with mitomycin C, which persisted to the maximum follow-up of 6 months. CONCLUSIONS: Mitomycin C treatment induces apoptosis of keratocytes and myofibroblasts, but the predominate effect in inhibiting or treating haze appears to be at the level of blocked replication of keratocytes or other progenitor cells of myofibroblasts. Treatment with 0.002% mitomycin C for 12 seconds to 1 minute appears to be just as effective as higher concentrations for longer duration in the rabbit model. However, a persistent decrease in keratocyte density in the anterior stroma could be a warning sign for future complications and treatment should be reserved for patients with significant risk of developing haze after PRK.
Authors: P S Hersh; R D Stulting; R F Steinert; G O Waring; K P Thompson; M O'Connell; K Doney; O D Schein Journal: Ophthalmology Date: 1997-10 Impact factor: 12.079
Authors: Ashish Tandon; Jonathan C K Tovey; Michael R Waggoner; Ajay Sharma; John W Cowden; Daniel J Gibson; Yuanjing Liu; Gregory S Schultz; Rajiv R Mohan Journal: J Refract Surg Date: 2012-03-01 Impact factor: 3.573
Authors: Carla S Medeiros; Luciana Lassance; Paramananda Saikia; Marcony R Santhiago; Steven E Wilson Journal: Exp Eye Res Date: 2018-03-27 Impact factor: 3.467
Authors: Rangan Gupta; Benjamin W Yarnall; Elizabeth A Giuliano; Jagat R Kanwar; Dylan G Buss; Rajiv R Mohan Journal: Vet Ophthalmol Date: 2011-04-18 Impact factor: 1.644
Authors: Jens Bühren; Lana Nagy; Jennifer N Swanton; Shawn Kenner; Scott MacRae; Richard P Phipps; Krystel R Huxlin Journal: Invest Ophthalmol Vis Sci Date: 2008-10-24 Impact factor: 4.799